JESSE I TREU
CIK 1013425 · last filed 2020-06-11
JESSE I TREU is a corporate insider who has filed 129 SEC Form 4 insider transactions across 27 companies since 2007. The most recent filing, for ALDX, was dated Jun 11, 2020. Across all open-market trades the lifetime net is +$33.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $85.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$85.39M
Companies
27
Total Filings
129
Lifetime Open-Market Net
$33.46M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALDX | Director | 1,877,091 | $1.70 | $3.19M | -$968.4K | 7 | 2020-06-11 |
| Vyome Holdings, Inc (OBLN) Delisted | 10%+ Owner | 271,144 | $9.15 | $2.48M | $24.00M | 2 | 2019-08-08 |
| VCYT | Director | 1,233,289 | $57.26 | $70.62M | -$26.86M | 8 | 2019-03-04 |
| Bionano Genomics, Inc. (BNGOU) Delisted | 10%+ Owner | 6,891 | — | — | $0 | 1 | 2018-08-27 |
| TNDM | Director | 318,906 | $18.10 | $5.77M | $0 | 5 | 2016-11-17 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Director | 0 | — | — | $0 | 4 | 2016-09-13 |
| SNDX | 10%+ Owner | 5,641 | $22.29 | $125.7K | $0 | 1 | 2016-03-08 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 23,197 | — | — | -$9.9K | 2 | 2015-08-20 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | Director | — | — | — | $0 | 1 | 2015-01-05 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 503,607 | — | — | $6.86M | 1 | 2014-12-10 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 16,529 | — | — | $7.06M | 3 | 2014-11-18 |
| OTONOMY, INC. (OTIC) Delisted | 10%+ Owner | 11,715 | $0.08 | $902 | $0 | 1 | 2014-08-18 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 33,890 | — | — | $0 | 1 | 2014-03-17 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 13,004 | $38.22 | $497.0K | $0 | 1 | 2014-02-04 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 254,274 | $5.54 | $1.41M | -$7.29M | 4 | 2014-01-17 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | Director | 1,908 | — | — | $3.00M | 2 | 2014-01-03 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 15,731 | — | — | $8.00M | 1 | 2013-07-16 |
| ESPR | 10%+ Owner | 1,786,012 | $3.18 | $5.68M | $4.00M | 1 | 2013-07-02 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 7,431,453 | — | — | $8.56M | 16 | 2013-04-10 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 5,731,874 | $0.08 | $465.4K | -$30.93M | 2 | 2013-03-06 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 5,772,968 | — | — | $0 | 3 | 2013-01-18 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 298,252 | — | — | $25.08M | 15 | 2011-12-22 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 1,240,417 | $26.68 | $33.09M | $16.40M | 2 | 2011-09-20 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 0 | — | — | -$1.31M | 17 | 2010-06-11 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | 10%+ Owner | 3,054,396 | — | — | -$514.6K | 3 | 2009-01-30 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 2,667,617 | — | — | -$1.59M | 9 | 2008-07-18 |
| SENORX INC (SENO) Delisted | Director | 21,915 | — | — | -$23.2K | 5 | 2008-02-27 |
Recent Filings
129 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-11 | ALDX | Grant (A) | — | $0 | EDGAR |
| 2019-08-08 | Vyome Holdings, Inc (OBLN) Delisted | Buy (P) | +1,500,000 | $6.00M | EDGAR |
| 2019-06-06 | ALDX | Grant (A) | — | $0 | EDGAR |
| 2019-03-28 | ALDX | Sell (S) | −96,743 | -$968.4K | EDGAR |
| 2019-03-04 | VCYT | Sell (S) | −1,052,151 | -$21.43M | EDGAR |
| 2018-08-27 | Bionano Genomics, Inc. (BNGOU) Delisted | Conv (C) | +41,346 | $69.0K | EDGAR |
| 2018-08-27 | Vyome Holdings, Inc (OBLN) Delisted | Buy (P) | +9,890,154 | $18.00M | EDGAR |
| 2018-08-02 | VCYT | Sell (S) | −500,000 | -$5.41M | EDGAR |
| 2018-06-11 | ALDX | Grant (A) | — | $0 | EDGAR |
| 2018-06-08 | VCYT | Grant (A) | — | $0 | EDGAR |
Showing 1–10 of 129
Page 1 of 13
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.